Eli Lilly (LLY) on Solana

Magnus Sigurdsson, co-founder of Systematic Ventures and partner at Iron Pine Ventures, is calling Eli Lilly the most probable acquirer of ATAI Life Sciences, estimating a takeover price of $9–$11 per share — up to 105% above ATAI's recent close. Sigurdsson notes that Lilly "appears to have decided that buying the entire company was preferable to licensing or purchasing only the drug," and considers a rival bidder unlikely given the formal sale process already underway. The deal would value ATAI above its roughly $2 billion market capitalization.

ATAI's lead asset, BPL-003, is a fast-acting nasal treatment for treatment-resistant depression that has received FDA Breakthrough Therapy designation and is currently in Phase 3 trials. The drug has shown symptom improvement within two days of a single dose, with benefits persisting up to eight weeks; the psychedelic effects resolve within about 90 minutes and the full clinical session runs approximately two hours — a profile that lowers the operational burden compared to longer psychedelic therapies. For Eli Lilly, acquiring ATAI would be a significant expansion of its neuroscience portfolio and would mark a major pharmaceutical commitment to psychedelic-derived medicine, a category that remains nascent but is drawing growing institutional attention.

The FDA has converted Retevmo (selpercatinib) from accelerated approval to traditional full approval, granting Eli Lilly a tumor-agnostic label that covers adult and pediatric patients with RET fusion solid tumors across a broader range of cancer types. The upgrade reflects confirmatory clinical data demonstrating durable efficacy and gives Lilly a wider addressable population beyond the narrower indications that anchored the drug's original clearance.

The full approval strengthens Lilly's oncology pillar at a time when the company is deliberately diversifying beyond its dominant GLP-1 franchise in obesity and diabetes. Retevmo competes in the growing targeted therapy space alongside Roche and Novartis, and the expanded label opens new commercial opportunities tied to genomic testing uptake — the more patients screened for RET fusions, the larger the eligible pool. Analysts will be watching oncology revenue contribution and physician adoption rates in coming quarters as a read on how meaningfully the drug can scale.

Eli Lilly's GLP-1 weight-loss franchise has become the dominant driver of the company's financials: Mounjaro and Zepbound together generated $12.8 billion in Q1 2026, roughly two-thirds of the company's $19.8 billion in total quarterly revenue. Mounjaro, the diabetes formulation of tirzepatide, grew 125% year-over-year to $8.7 billion, while Zepbound, its obesity counterpart, added $4.2 billion — up 80% from the prior year. The combined franchise produced $36.5 billion for full-year 2025, and Lilly raised its 2026 revenue guidance to $82–85 billion, implying roughly 28% growth. Adjusted EPS guidance was also lifted by $2 to a range of $35.50–$37.00 per share.

The company launched Foundayo in April 2026 — an orforglipron-based once-daily GLP-1 pill for obesity priced from $149 per month — adding an oral option to its injectable portfolio. The franchise's rapid expansion has pushed Lilly's market cap to approximately $1.06 trillion. One risk investors are watching: with nearly two-thirds of revenue tied to a single molecule, any pricing pressure or competitive disruption carries outsized impact; the company's realized prices already declined 13% in Q1 due partly to cash-pay discounts on Zepbound.

Eli Lilly will present updated safety and biomarker findings from its Kisunla (donanemab-azbt) Alzheimer's program at the 2026 Alzheimer's Association International Conference (AAIC), alongside new data on its P-tau217 blood-based diagnostic test. The P-tau217 assay is designed to support broader Alzheimer's screening by offering a less invasive alternative to PET scans or cerebrospinal fluid testing, which could meaningfully expand the eligible patient population for treatments like Kisunla.

The AAIC presentations represent an important clinical narrative moment for Lilly as it looks to establish Alzheimer's as a third major revenue pillar alongside its dominant GLP-1 franchise and oncology portfolio. Broader adoption of Kisunla hinges on regulatory and payer acceptance of its safety-benefit profile relative to competitors Biogen and Eisai, and the scalability of accessible blood-based diagnostics will be a key factor in how quickly the market develops.

Eli Lilly's obesity drug business is increasingly a global story, with international revenue rising 81% to $7.7 billion in the most recent quarter as the company's GLP-1 footprint expands well beyond the U.S. Mounjaro, the company's tirzepatide-based diabetes and obesity treatment, was fully launched in more than 55 countries as of Lilly's first-quarter 2026 earnings call, up from over 40 a year earlier. Key 2025 market entries in Mexico and Brazil have become significant sources of overseas demand, while China saw a limited-capacity launch in late 2024.

In Q1 2026, Mounjaro generated $8.66 billion in revenue, up 125% year over year, and Zepbound — the weight-loss-specific formulation — contributed $4.16 billion with U.S. revenue up 80%. With obesity treatment adoption still at an early stage across much of the world, the geographic diversification of Lilly's GLP-1 business reinforces analyst projections that the company's revenue runway extends well into the next decade.

Eli Lilly is broadening its pipeline through two external partnerships that reflect a strategy of accessing outside science while adapting to regional commercial realities. The company has entered a research collaboration with Abbisko Therapeutics, a Shanghai-based oncology biotech, to expand its drug discovery capacity beyond purely in-house development. Financial terms of the Abbisko deal were not disclosed.

On the China commercialization front, Lilly has transferred commercial rights for Verzenios — its breast cancer treatment — to Innovent Biologics for the Chinese market. The move represents a deliberate retrenchment in how Lilly manages its China presence, concentrating its direct commercial effort on obesity and diabetes franchises such as Zepbound while leaning on local partners to carry other therapy areas. Together, the moves illustrate Lilly's preference for alliances to shape its long-term therapy mix, rather than relying solely on internal development and global direct commercialization. Outcomes remain contingent on research progress, regulatory decisions, and partner execution.

Eli Lilly's tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for obesity — generated more than $12 billion combined in the company's most recent quarter, cementing Lilly's position as the leading GLP-1 drug maker globally. The company holds roughly 60% of the U.S. GLP-1 market and 53% internationally, having overtaken Novo Nordisk approximately one year ago. A newly FDA-approved oral formulation, Foundayo, adds a daily pill option that analysts expect to broaden the addressable market as patients who prefer not to inject gain access to tirzepatide.

The long-term investment case rests on projections that the global GLP-1 drug market will approach $100 billion by the end of the decade, with Lilly positioned to capture a dominant share across both injectable and oral formats. LLY shares trade around $1,000 at roughly 32 times forward earnings — compressed from over 40 times earlier — which analysts characterize as reasonable given the scale and durability of the GLP-1 opportunity. The stock has gained more than 50% over the past year.

A valuation analysis of Eli Lilly (LLY) at roughly $1,213 per share presents a split picture depending on which lens is applied. On a discounted cash flow basis, trailing twelve-month free cash flow of $8.6 billion produces an intrinsic value estimate of approximately $1,591 per share — implying the stock may trade around 24% below its modeled fair value if the company's GLP-1-driven cash generation continues to grow. That bullish read, however, assumes sustained momentum from the obesity and diabetes franchise and expanding Medicare coverage under the GLP-1 Bridge program.

The earnings-based view is less compelling. LLY's forward P/E of 42.8x sits well above both the pharmaceutical industry average of 15.4x and the peer-group average of 25.2x, though the analysis pegs a "tailored fair P/E" for Lilly at 39.2x given its growth profile — placing the stock only modestly above that threshold. Overall, the stock passes just two of six valuation checks in the framework, suggesting investors are pricing in significant execution on the GLP-1 pipeline while accepting elevated multiple risk if pricing pressure or regulatory headwinds slow revenue growth.
---

Eli Lilly's growing dependence on GLP-1 weight-loss drugs — which now account for nearly two-thirds of its revenues — is drawing increased scrutiny as Johnson & Johnson publicly distances itself from the roughly $100 billion obesity drug market. J&J CEO Joaquin Duato is instead focusing the company on oncology franchises covering bone, lung, and prostate cancers, as well as its medical device segment producing surgical tools and joint replacements. The strategic divergence frames Lilly's dominance in GLP-1s as both its primary growth engine and its most significant concentration risk.

The valuation gap between the two companies reflects those contrasting bets. Lilly trades at over 40x earnings with a dividend yield of just 0.6%, pricing in continued GLP-1 leadership in a market where competitive pressure is intensifying. J&J trades at roughly 29x earnings with a 2.1% yield, offering what some analysts characterize as a more defensible entry point backed by multiple independent revenue streams. Whether Lilly's GLP-1 lead sustains those multiples or becomes a liability depends largely on how quickly rivals can close the gap in a market that remains Lilly's to lose.

Medicare's Bridge demonstration program began covering GLP-1 obesity drugs on July 1, 2026 — the first time the federal program has covered these medications solely for weight loss. Eli Lilly's Zepbound (KwikPen injection) and its oral formulation Foundayo are among the covered drugs, alongside Novo Nordisk's Wegovy. Eligible beneficiaries pay a flat $50 monthly copay, a steep discount from Zepbound's typical out-of-pocket cost of $299–$699 per month. Coverage extends to Medicare enrollees with a BMI of 35 or higher, or a lower BMI combined with conditions such as prediabetes, prior heart attack or stroke, or blocked arteries — a pool estimated at 15–20 million older adults nationally.

Analysts project the program could generate over $1 billion annually for Lilly, which currently holds roughly 60% of the U.S. GLP-1 obesity market. The coverage requires prior authorization, and the program is set to expire at the end of 2027 unless extended by Congress or through separate insurer agreements. That expiration timeline creates uncertainty for patients who may begin what experts consider lifelong treatment, but the immediate effect is a significant expansion of Lilly's addressable Medicare population for Zepbound.